This is why I love this forum so much...it because of questions...

This is why I love this forum so much...it because of questions such as the one that PseudonymABC asks that makes me and so many (better) other posters to research about our great PAR.

Ok SO I did a bit of research and I haven't had much luck finding much about standalone Aussie listed companies that have gone through successful Phase 3 trials in the past. I fell back to CUV...its sort of the closest thing I can find but it is also quite different from our situation. The differences are that they already had some European sales at the time their NDA was filed with the USA and of course its a totally different development and there are other factors make it different to our situation but we can still learn something from it, this is what I found.

Their FDA filing was for a Priority type designation and that happened on 25th June 2018. The immediate impact of their SP was a lift from $10.78 to $11.97...whats that, 11%..that would equate to us resulting in a lift from $1.60 (assuming that what we are at now) to $1.77...remember, our situation is different compared to CUV and also compared to what CUV was at the time (last year)...so who really knows.

Interestingly (and this to me is quite insightful) they had a large conference in New York just a few months after that to present what they are all about , this had the impact of a SP lift from $14.56 to $18.34..that's a large 26% lift...SO what does this mean? This means that US Institutions must've caught on and started buying in. Volume on the 25th of Aug (IND filing) was a bit higher than average at the time but volume on/around the NY conference was double.

As further proof of the sway of the large instos, on the 25th of Sep 2018 CUV had a virtual conference with NASDAQ and this resulted in a massive 8 X volume spike.

All speculation here, my opinions etc but it gives us some possible insight.


CUV - FDA Filing for Priority NDA



New York Presentation - News



NASDAQ Presentation news